Juva Life Recordsdata Patent on Household of Non-Cannabinoid Small Molecules Concentrating on Shopper and Pharma Inflammatory Indications

Article content material

VANCOUVER, British Columbia, Oct. 14, 2021 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV)  (“Juva Life,” “Juva” or the “Firm”), a California based mostly life sciences firm centered on the analysis, improvement, and commercialization of Hashish merchandise right this moment introduced the development of the JUVA-19 class of compounds into formal improvement.

JUVA-19 is a non-cannabinoid small molecule remoted from hashish with earlier unappreciated broad spectrum anti-inflammatory properties. Pre-clinical outcomes show that JUVA-19 inhibits IL1-beta and TNF-alpha in a dose dependent method. Moreover, the corporate has recognized candidate targets in step with the regulation of oxidative stress and irritation.

Article content material

Juva Life is availing itself of the numerous physique of literature suggestive of therapeutic advantages of hashish coupled to trendy drug discovery and deep studying instruments. The corporate’s technique is to develop pure and semi-synthetic compositions alone and together for the patron anti-inflammatory market, and in parallel chemically optimize compositions for choose pharmaceutical indications.

The Firm’s enterprise technique is to leverage its distinctive information of the chemistry and anti inflammatory mode of motion of non-cannabinoid compositions contained inside hashish to develop protected and efficient therapeutics. The corporate intends to develop merchandise via pre-clinical in vivo validation research, and accomplice with main pharma and shopper firms in search of anti-inflammatory bioactives for his or her product pipelines. On October 6, 2021, the corporate filed a provisional patent with america Patent and Trademark Workplace (USPTO) on technique of use of the pure compositions, and composition of matter claims on non-naturally occurring semi-synthetic and artificial analogs.

Article content material

Firm CEO, Doug Chloupek states, “We’re happy of the progress of our inside analysis and improvement actions.” Mr. Chloupek continues, “Our subsequent steps are to construct upon our preliminary findings by profiling the Juva-019 class of compounds in gold normal in-vivo fashions of irritation, paving the way in which for evidenced-based product improvement.”

In separate information, the Firm is happy to announce the appointment of Dr. Peter Beitsch to its Board of Administrators, efficient instantly.

Dr. Beitsch has held quite a few positions in nationwide surgical societies together with the American Society of Breast Surgeons the place he served as President of the Society from 2013-14, first Chairman of the Membership Committee 2001-4, Program Director for the 2005 Annual Assembly in Los Angeles, Board of Administrators Member from 2006-9 and 2012-15. He has served on the Govt Committee of the Society of Surgical Oncology 2008-2010, Normal Surgical Oncology Committee of the American Board of Surgical procedure and was a Nationwide Ultrasound School for the American Faculty of Surgeons.

Article content material

Dr. Beitsch has introduced internationally and is actively concerned in breast most cancers and melanoma analysis. He has authored main articles in peer-reviewed medical journals together with the New England Journal of Drugs, the Journal of the American Medical Affiliation, the Proceedings of the Nationwide Academy of Science, Journal of Medical Oncology, and the Annals of Surgical Oncology.

Firm CEO, Doug Chloupek states, “I’m more than happy to welcome Dr. Beitsch to our Board right this moment. The timing is superb as we ramp our investigative endeavors into new and thrilling compounds. Dr. Beitsch has supplied wonderful recommendation, and insights via his earlier position as an adviser to the Firm and we’re trying ahead to his expanded position.”

Article content material

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder
Juva Life Inc.
inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is using state-of-the-art science to find, develop and commercialize protected and efficient Hashish merchandise. The Firm is efficiently executing in opposition to its 2018 roadmap, initially beginning with standardization of cultivation, extraction, and formulation to supply shoppers reproducible advantages. Juva is constructing upon these pure product course of chemistry expertise, to now embody discovery pharmacology. The Firm will leverage income derived from its retail operations to advance Juva-019 and different doubtlessly precious non-cannabinoid bioactives for shopper and pharma merchandise purposes. Juva is working to deliver the Hashish market head to head with the sector’s subsequent technology funding grade enterprise mannequin. Discover out extra at:  https://juvalife.com/ . 

Article content material

For additional data, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
E mail: inquiries@juvalife.com

Ahead Wanting Assertion
This information launch accommodates statements and knowledge that, to the extent that they don’t seem to be historic reality, might represent “forward-looking data” throughout the that means of relevant securities laws. Ahead-looking data might embody monetary and different projections, in addition to statements relating to future plans, aims, or financial efficiency, or the belief underlying any of the foregoing. In some circumstances, forward-looking statements might be recognized by phrases resembling “might”, “would”, “may”, “will”, “probably”, “besides”, “anticipate”, “imagine”, “intend”, “plan”, “forecast”, “undertaking”, “estimate”, “outlook”, or the adverse thereof or different comparable expressions regarding issues that aren’t historic details. Examples of such statements embody, however usually are not restricted to, statements with respect to the aims and enterprise plans of the Firm; product improvement, commercialization technique and future collaborations.

Article content material

Ahead-looking data includes recognized and unknown dangers, uncertainties and different elements which will trigger the precise outcomes, efficiency or achievements of the Firm to vary materially from any future outcomes, efficiency or achievements expressed or implied by the forward-looking data, together with, with out limitation, dangers referring to the longer term enterprise plans of the Firm; dangers that the Firm will be unable to retain its key personnel; dangers that the Firm will be unable to safe financing on cheap phrases or in any respect, in addition to the entire different dangers as described within the Firm’s administration dialogue and evaluation for yr ended December 31, 2020 below the heading “Dangers and Uncertainties”. Accordingly, readers mustn’t place undue reliance on any such forward-looking data. Additional, any forward-looking data speaks solely as of the date on which such assertion is made. New elements emerge infrequently, and it’s not potential for the Firm’s administration to foretell all of such elements and to evaluate upfront the influence of every such issue on the Firm’s enterprise or the extent to which any issue, or mixture of things, might trigger precise outcomes to vary materially from these contained in any forward-looking data. The Firm doesn’t undertake any obligation to replace any forward-looking data to mirror data or occasions after the date on which it’s made or to mirror the prevalence of unanticipated occasions, besides as required by legislation, together with securities legal guidelines.

The CSE doesn’t settle for accountability for the adequacy or accuracy of this launch.